Tetrahydrocannabinol

Phase 3Small molecule

HHadassah Medical Organization

Tetrahydrocannabinol is one of 191 small molecule programs targeting Memory. It is currently in Phase 3.

Indications

Total Trials

Active Trials

190

Competitors

Pipeline

Status by Indication[3][1]

Indication

MemoryActive, not recruiting

FibromyalgiaActive, not recruiting

Osteoarthritis, KneeRecruiting

FunctionCompleted

Cannabis UseRecruiting

Post-Traumatic Stress DisorderUnknown status

MemoryPreclinical

Active, not recruiting

FibromyalgiaPreclinical

Active, not recruiting

Osteoarthritis, KneePhase 2

Recruiting

FunctionPreclinical

Completed

Cannabis UsePreclinical

Recruiting

Post-Traumatic Stress DisorderPhase 3

Unknown status

Competition

Competitive Landscape

61 competitors in Post-Traumatic Stress Disorder

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

5 2

Minipress

Pfizer

Approved

4 3

Epidiolex

Jazz Pharmaceuticals

Approved

2 4

Ritalin

Novartis

Approved

1 5

Namenda

AbbVie

Approved

1 6

Revia

Teva

Approved

1 7

Marinol

Jazz Pharmaceuticals

Approved

1 8

Zoloft

VViatris Specialty LLC

Approved

7 9

Inderal

WWyeth-Lederle Vaccines

Approved

5 10

Cymbalta

Jazz Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Osteoarthritis, Knee

NCT04992624

Q3 2027

Phase 2Recruiting

Multiple Sclerosis

NCT05269628

Q4 2027

Phase 1Recruiting

Study completion

NCT06772753

Q4 2030

PreclinicalRecruiting

Post-Traumatic Stress Disorder

NCT06381180

Clinical

Trials by Indication[1]

Post-Traumatic Stress Disorder2 trials

Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)

Unknown status·HHadassah Medical Organization·Phase 4·NCT00965809·70 enrolled

Wayne Warrior CAnnabis Research and Education: Cannabis and Behavioral Health

Recruiting·WWayne State University·Preclinical·NCT06381180·500 enrolled

Fibromyalgia1 trial

Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia

Unknown status·HHadassah Medical Organization·N/A·NCT01149018·80 enrolled

Abdominal pain1 trial

The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain

Completed·RRadboud University Medical Center·Phase 2·NCT01562483·36 enrolled

Function1 trial

Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD)

Completed·—·N/A·NCT02291536·20 enrolled

Marijuana1 trial

Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2

Completed·WWayne State University··NCT00218504·20 enrolled

7 more indications

Cannabis Use1 trial

The Efficacy of a Smart Phone-based Test on Measuring Pupillary Light Reflex Alterations Following Cannabis Use Healthy in Adults

Recruiting·SSobereye Inc.·N/A·NCT06967051·20 enrolled

Memory1 trial

Effects of THC and CBD on Human Episodic Memory Function

Completed·—·N/A·NCT02291562·20 enrolled

Premedication1 trial

Anesthetic Premedication With a Cannabis Extract (Cannapremed)

Unknown status·HHadassah Medical Organization·Phase 2/3·NCT02283281·200 enrolled

Chronic Pancreatitis1 trial

Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain

Completed·RRadboud University Medical Center·Phase 2·NCT01551511·29 enrolled

Osteoarthritis, Knee1 trial

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Recruiting·SSteven E Harte, PhD·Phase 2·NCT04992624·200 enrolled

Multiple Sclerosis1 trial

Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype

Recruiting·TTiffany J. Braley, MD, MS·Phase 2·NCT05269628·166 enrolled

Unspecified2 trials

Investigation of Psychedelic Effects in Psychoactive Substances

Recruiting·JJohns Hopkins University·Phase 1·NCT06772753·50 enrolled

The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking

Completed·WWageningen University·N/A·NCT02112292·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Tetrahydrocannabinol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tetrahydrocannabinol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tetrahydrocannabinol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hadassah Medical Organization company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHadassah Medical Organization

Tetrahydrocannabinol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q4 2030

Trials by Indication[1]

Post-Traumatic Stress Disorder2 trials

Fibromyalgia1 trial

Abdominal pain1 trial

Function1 trial

Marijuana1 trial

Cannabis Use1 trial

Memory1 trial

Premedication1 trial

Chronic Pancreatitis1 trial

Osteoarthritis, Knee1 trial

Multiple Sclerosis1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News